Search our team at AdventHealth Research Institute
-
NCT05932615
Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients who have Severe, Symptomatic, Aortic Stenosis Requiring Aortic Valve Replacement
This study is currently enrolling.Associated Conditions: Aortic StenosisResearch Area: Heart, Lung and Vascular ResearchResearch Location: Orlando, FloridaAortic stenosis is a type of heart valve disease where the valve located between the lower left heart chamber and the body’s main artery (aorta) becomes narrowed and cannot open completely. This...
-
NCT06457997
First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients with Advanced Solid Tumors
This study is currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThe Sponsor will use tumor tissue samples along with other health information collected during the main study to conduct exploratory research in order to learn about the following: Why some people...
-
rhPSMA-7.3(18F)-PET scan to detect prostate cancer in patients with early PSA recurrence.
This study is currently enrolling.Associated Conditions: Prostate CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe research is being done at the Radiology Nuclear Medicine Department of AdventHealth Orlando and Celebration. Patients are instructed to drink water prior to administration of flotufolastat F-18 to...
-
NCT05940857
Sponsor-Initiated OCS Liver Perfusion (OLP-II) Registry
This study is currently enrolling.Research Area: Transplant ResearchResearch Location: Orlando, FloridaThe objective of the sponsor-initiated OLP-II Registry is to collect data on the post-transplant clinical outcomes of donor livers preserved and assessed on OCS Liver System and to document...
-
NCT06346392
D9802C00001 (CLARITY GC01): A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
This study is currently enrolling.Associated Conditions: Esophageal CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaWe are doing this study to learn more about: the effectiveness and safety of the investigational study drug AZD0901 compared to a standard therapy that will be selected by your study doctor per your...
-
NCT05858164
An open-label, phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics, and tumor response profile of the diacylglycerol kinase alpha inhibitor (DGKai) BAY 2862789 in participants with advanced solid tumors
This study is currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThis study is being done to learn more about a new drug called BAY 2862789, an inhibitor of diacylglycerol kinase alpha (DGKα). BAY 2862789 is an immunotherapy drug that has been developed to activate...
-
NCT04073563
Prospective, Randomized, Controlled, Blinded Pivotal Study In Subjects Undergoing A Transforaminal Lumbar Interbody Fusion (TLIF) At One Or Two Levels Using Infuse™ Bone Graft With an Intervertebral Body Fusion Device and Posterior Supplemental Fixation For The Treatment Of Symptomatic Degenerative Disease Of The Lumbosacral Spine
This study is currently enrolling.Research Area: Neuroscience ResearchResearch Location: Orlando, FloridaThe purpose of this study is to evaluate the Infuse™ Bone Graft in combination with other spinal devices and autograft bone (your own bone) to see if it is safe and effective when used in a TLIF...
-
NCT05918913
SNDX-5613-0707: Expanded Access Program for SNDX-5613 in Patients with Relapsed/Refractory Acute Leukemias with Genetic Alterations Associated with HOXA Overexpression
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe therapy that will be receive involves being given the drug SNDX-5613 to treat Relapsed/Refractory acute leukemias, including those harboring an KMT2Ar Gene Rearrangement, Nucleophosmin 1 (NPM1m)...
-
NCT06290141
A Phase 3, randomized, double-blind, study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (IVIg) in participants with chronic inflammatory demyelinating polyneuropathy
This study is currently enrolling.Research Area: Neuroscience ResearchResearch Location: Orlando, FloridaA Phase 3, randomized, double-blind, study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (IVIg) in participants with chronic inflammatory demyelinating polyneuropathy...
-
NCT05442216
TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaWe are doing this study because we want to find out if this approach will provide a longer period of disease response and is safe. The researchers conducting this study plan to publish the...
-
NCT06226571
A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to find the best dose of revumenib taken with other cancer drugs, known as chemotherapy, and to find out what side effects happen after you take this study drug. It will...
-
NCT06384261
A multicenter, open label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy.
This study is currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to see if the investigational study drug, called cusatuzumab, is safe and effective when given together with other standard of care drugs used to treat Acute Myeloid...